- Previous Close
24.60 - Open
24.40 - Bid 24.00 x --
- Ask 25.00 x --
- Day's Range
24.20 - 24.60 - 52 Week Range
19.00 - 28.00 - Volume
451 - Avg. Volume
534 - Market Cap (intraday)
294.959M - Beta (5Y Monthly) -0.07
- PE Ratio (TTM)
15.67 - EPS (TTM)
1.57 - Earnings Date Apr 15, 2025
- Forward Dividend & Yield 1.36 (5.53%)
- Ex-Dividend Date Jun 27, 2024
- 1y Target Est
38.75
PharmaSGP Holding SE manufactures and sells over-the-counter drugs and other healthcare products in Germany. The company's pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage creams for the treatment of various pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Revitensin, a drug for the treatment of hair loss; Dorisol for neuralgia (nerve pain), headaches, and migraines; Fulminan, a beauty drink; Lindaven, a pharmaceutical drops to treat their unpleasant problem; and SCLEROCALMAN, a drug for the treatment of clogged cerebral blood vessels. It also offers Prostacalman, a medication for cystitis and urination discomfort in a benign enlarged prostate; Revoten for women with weak connective tissue; Mindalin, a micronutrient drink for a healthy cardiovascular system; MELISTON, a prescription-free tablets to treat anxiety, restlessness, and mood swings; Deruba, a cream for skin redness; Lentisol that prevents the formation of new pigment spots; Neodolor, a headache tablet; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo. The company sells its products through pharmacies and wholesalers. It also exports its products to European countries comprising Austria, Italy, Belgium, Spain, and France. The company was founded in 2012 and is based in Gräfelfing, Germany.
pharmasgp.com89
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: PSG.DE
View MorePerformance Overview: PSG.DE
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PSG.DE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PSG.DE
View MoreValuation Measures
Market Cap
294.96M
Enterprise Value
257.80M
Trailing P/E
15.67
Forward P/E
10.25
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.59
Price/Book (mrq)
7.98
Enterprise Value/Revenue
2.26
Enterprise Value/EBITDA
6.66
Financial Highlights
Profitability and Income Statement
Profit Margin
16.49%
Return on Assets (ttm)
12.85%
Return on Equity (ttm)
51.14%
Revenue (ttm)
114M
Net Income Avi to Common (ttm)
18.8M
Diluted EPS (ttm)
1.57
Balance Sheet and Cash Flow
Total Cash (mrq)
37.77M
Total Debt/Equity (mrq)
189.24%
Levered Free Cash Flow (ttm)
20.73M